JAK/STAT3 signaling pathway is often deregulated in hematopoietic disorders including peripheral T-cell lymphoma. We describe two novel mechanisms leading to the constitutive activation of STAT3 in ALK- ALCL. Oncogenic JAK1 or STAT3 mutations are associated to hyperactive pSTAT3 that regulated canonical STAT3 and ATF3 genes. Moreover, synergizing JAK1 and STAT3 mutants sustain the neoplastic growth, which can be efficiently controlled in vitro and in an ALCL patient derived tumorgraft model by JAK1/2 inhibitors. We have discovered that novel chimera, displaying concomitant transcriptional and kinase activities, are power oncogenes capable to sustain via STAT3 the ALCL phenotype and can be uniquely neutralized by a novel ROS1 inhibitor. The pharmacological inhibition of JAK/STAT3 represents a novel strategy for the treatment of molecular stratified ALCL.

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma / Ramona, Crescenzo; Francesco, Abate; Elena, Lasorsa; Fabrizio, Tabbo’; Marcello, Gaudiano; Nicoletta, Chiesa; Filomena Di, Giacomo; Elisa, Spaccarotella; Luigi, Barbarossa; Elisabetta, Ercole; Maria, Todaro; Michela, Boi; Acquaviva, Andrea; Ficarra, Elisa; Domenico, Novero; Andrea, Rinaldi; Thomas, Tousseyn; Andreas, Rosenwald; Lukas, Kenner; Lorenzo, Cerroni; Alexander, Tzankov; Maurilio, Ponzoni; Marco, Paulli; Dennis, Weisenburger; Wing C., Chan; Javeed, Iqbal; Miguel A., Piris; Alberto, Zamo’; Carmela, Ciardullo; Davide, Rossi; Gianluca, Gaidano; Stefano, Pileri; Enrico, Tiacci; Brunangelo, Falini; Leonard D., Shultz; Laurence, Mevellec; Jorge E., Vialard; Roberto, Piva; Francesco, Bertoni; Raul, Rabadan; Giorgio, Inghirami. - In: CANCER CELL. - ISSN 1535-6108. - 27:4(2015), pp. 516-532. [10.1016/j.ccell.2015.03.006]

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

FICARRA, ELISA;
2015

Abstract

JAK/STAT3 signaling pathway is often deregulated in hematopoietic disorders including peripheral T-cell lymphoma. We describe two novel mechanisms leading to the constitutive activation of STAT3 in ALK- ALCL. Oncogenic JAK1 or STAT3 mutations are associated to hyperactive pSTAT3 that regulated canonical STAT3 and ATF3 genes. Moreover, synergizing JAK1 and STAT3 mutants sustain the neoplastic growth, which can be efficiently controlled in vitro and in an ALCL patient derived tumorgraft model by JAK1/2 inhibitors. We have discovered that novel chimera, displaying concomitant transcriptional and kinase activities, are power oncogenes capable to sustain via STAT3 the ALCL phenotype and can be uniquely neutralized by a novel ROS1 inhibitor. The pharmacological inhibition of JAK/STAT3 represents a novel strategy for the treatment of molecular stratified ALCL.
2015
27
4
516
532
Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma / Ramona, Crescenzo; Francesco, Abate; Elena, Lasorsa; Fabrizio, Tabbo’; Marcello, Gaudiano; Nicoletta, Chiesa; Filomena Di, Giacomo; Elisa, Spaccarotella; Luigi, Barbarossa; Elisabetta, Ercole; Maria, Todaro; Michela, Boi; Acquaviva, Andrea; Ficarra, Elisa; Domenico, Novero; Andrea, Rinaldi; Thomas, Tousseyn; Andreas, Rosenwald; Lukas, Kenner; Lorenzo, Cerroni; Alexander, Tzankov; Maurilio, Ponzoni; Marco, Paulli; Dennis, Weisenburger; Wing C., Chan; Javeed, Iqbal; Miguel A., Piris; Alberto, Zamo’; Carmela, Ciardullo; Davide, Rossi; Gianluca, Gaidano; Stefano, Pileri; Enrico, Tiacci; Brunangelo, Falini; Leonard D., Shultz; Laurence, Mevellec; Jorge E., Vialard; Roberto, Piva; Francesco, Bertoni; Raul, Rabadan; Giorgio, Inghirami. - In: CANCER CELL. - ISSN 1535-6108. - 27:4(2015), pp. 516-532. [10.1016/j.ccell.2015.03.006]
Ramona, Crescenzo; Francesco, Abate; Elena, Lasorsa; Fabrizio, Tabbo’; Marcello, Gaudiano; Nicoletta, Chiesa; Filomena Di, Giacomo; Elisa, Spaccarotel...espandi
File in questo prodotto:
File Dimensione Formato  
Cancer Cell_2015_Inghirami.pdf

Accesso riservato

Dimensione 5.9 MB
Formato Adobe PDF
5.9 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1240376
Citazioni
  • ???jsp.display-item.citation.pmc??? 199
  • Scopus 355
  • ???jsp.display-item.citation.isi??? 330
social impact